Full publication list
- Measles and rubella elimination country profile - Denmark (2020)
- "Immunity passports” in the context of COVID-19: scientific brief, 24 April 2020
- 10th Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- 11th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- 11th meeting of the Measles/Rubella Regional Reference Laboratories of the WHO European Region (2016)
- 12th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- 12th Meeting of the measles/rubella regional reference laboratories of the WHO European Region (2017)
- 13th meeting of the European Measles and Rubella Regional Reference Laboratories. Report (2018)
- 13th meeting of the European Technical Advisory Group of Experts on Immunization
- 14th meeting of the measles/rubella regional reference laboratories of the WHO European Region (2020)
- 15th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- 16th ETAGE meeting report
- 18th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE) (2018)
- 19th meeting of the European Technical Advisory Group of Experts on immunization (ETAGE) (2019)
- 2013 Guide to tailoring immunization programmes
- 20th meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE) (2020)
- 28th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication
- 29th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication (RCC)
- 30th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication
- 31st meeting of the Regional Certification Commission for Poliomyelitis Eradication (2017)
- 32nd Meeting of the European Regional Commission for Certification of Poliomyelitis Eradication (RCC) Report (2018)
- 33rd meeting of the European Regional Commission for Certification of Poliomyelitis Eradication (RCC) Report (2019)
- 3rd meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC)
- 4th Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC)
- 5th meeting of the European Regional Verification Commission for Measles and Rubella Elimination (2017)
- 6th meeting of the Regional Verification Commission for Measles and Rubella Elimination (RVC)
- 7 key reasons to immunize
- 7th meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC). Report (2018)
- 9th Meeting of the Measles Rubella Reference Laboratories of the WHO European Region
- Ad-hoc meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE): virtual meeting, hosted in Copenhagen, Denmark, 28 April 2021
- Antigenic and genetic characteristics of zoonotic influenza viruses and candidate vaccine viruses developed for potential use in human vaccines (2017)
- Assessing the magnitude and nature of shortages of essential medicines and vaccines: focus on the WHO European Region (2020)
- Best practice guidance: How to respond to vocal vaccine deniers in public (2017)
- Brochure on collaboration with Lions Clubs International towards elimination of measles and rubella (2015)
- Case study Armenia – rotavirus
- Case study Belarus and Uzbekistan – Hib
- Case study Croatia – PCV
- Case study Georgia – PCV
- Case study Germany – measles
- Case study Germany – rotavirus
- Case study Italy – hepatitis B
- Case study Italy – measles
- Case study United Kingdom – measles
- Case study United States – polio
- Communicating with patients about COVID-19 vaccination: evidence-based guidance for effective conversations to promote COVID-19 vaccine uptake (2021)
- Consultation with Member States of the WHO European Region on use of immunization data for decision (2018)
- Cost-effectiveness case studies (2015)
- Crisis preparedness
- Crisis response
- Cross-country collaborations to improve access to medicines and vaccines in the WHO European Region (2020)
- Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021
- Effective communication of immunization data (2019)
- Eighth Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- EIW 2008 highlights
- EIW 2012 Core Communications Package
- EIW folder
- EIW Guidelines for PR and working with the media
- EIW national planning guidelines
- EIW poster
- EIW stickers
- EIW T-shirt
- Eliminating measles and rubella. Framework for the verification process in the WHO European Region
- English–Russian glossary of key terms on vaccinology and immunization
- Enterovirus surveillance guidelines. Guidelines for enterovirus surveillance in support of the Polio Eradication Initiative
- Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design: guidance document (2021)
- European Immunization Week 2005
- European Immunization Week 2007
- European Immunization Week 2010 Narrative Report
- European Immunization Week 2011: Narrative Report
- European Immunization Week 2012: Narrative Report
- European Immunization Week 2013: Narrative Report
- European Immunization Week 2014: Narrative Report
- European Immunization Week 2015: Narrative Report
- European Immunization Week 2016: Narrative Report
- European Regional Meeting of National Immunization Programme Managers (2017)
- European Technical Advisory Group of Experts on Immunization (ETAGE) interim recommendations, June 2021: inclusion of adolescents aged 12–15 years in national COVID-19 vaccination programmes (2021)
- European Vaccine Action Plan 2015–2020 (2014)
- European Vaccine Action Plan midterm report (2018)
- Evaluation: European Immunization Week 2009
- Extraordinary meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- Facilitator’s guide: communicating with patients about COVID-19 vaccination (2021)
- Fact sheet for health workers: Comirnaty® Pfizer/BioNTech BNT162b2 vaccine (international nonproprietary name: tozinameran) (2021) (produced by WHO/Europe)
- Fact sheet for health workers: Moderna COVID-19 (mRNA-1273) vaccine (2021)
- Field guide to qualitative research for new vaccine introduction
- Fifth Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- First European Immunization Week meeting
- Fourth Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region (2013)
- Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region, 20 March 2020 (produced by WHO/Europe)
- Guidelines for measles and rubella outbreak investigation and response in the WHO European Region
- Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020
- Health system considerations: when influenza meets COVID-19, revised version December 2020 (produced by WHO/Europe)
- Health workers in focus: policies and practices for successful public response to COVID-19 vaccination: strategic considerations for member states in the WHO European region (2021) (produced by WHO/Europe)
- High coverage – continual outbreaks
- Highlights of European Immunization Week 2017 – Narrative report
- Highlights of European Immunization Week 2018
- Highlights of European Immunization Week 2019. Report on regional and country activities (2019)
- How to prepare a financial profile of your immunization programme
- How to present the wider societal benefits of immunization
- How to respond to concerns about vaccination (2017)
- HPV – facts about the virus, the vaccine and what this means for you.Answers to common questions asked by adolescents and young adults (2017)
- If You Choose Not to Vaccinate Your Child, Understand the Risks and Responsibilities
- Immunization Highlights 2011-2012
- Immunization Highlights 2015
- Immunization highlights: European Vaccine Action Plan progress report for 2016
- Influenza: signs, symptoms & complications; recommendations for prevention
- Infographic – HPV vaccination (2013)
- Information sheet – European Vaccine Action Plan 2015–2020
- Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, 17 March 2021
- Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, first issued 17 March 2021, updated 15 June 2021
- Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID19 developed by Oxford University and AstraZeneca: interim guidance, 10 February 2021
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: interim guidance, 7 May 2021
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, 25 January 2021
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, first issued 25 January 2021, updated 15 June 2021
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, 8 January 2021
- Job aid for COVID-19 vaccine administration: AZD1222 (ChAdOx1-S [recombinant]) COVID-19 vaccine* (International nonproprietary name: COVID-19 Vaccine (ChAdOx1-S [recombinant])) (2021) (produced by WHO/Europe)
- Job aid for COVID-19 vaccine administration: Comirnaty® Pfizer/BioNTech BNT162b2 vaccine (international nonproprietary name: tozinameran) (2021) (produced by WHO/Europe)
- Job aid for COVID-19 vaccine administration: Moderna COVID-19 (mRNA-1273) vaccine (2021)
- Links to regional and global immunization data
- Measles and rubella country profile – Albania (2018)
- Measles and rubella country profile – Albania (2019)
- Measles and rubella country profile – Andorra (2018)
- Measles and rubella country profile – Andorra (2019)
- Measles and rubella country profile – Armenia (2018)
- Measles and rubella country profile – Armenia (2019)
- Measles and rubella country profile – Austria (2018)
- Measles and rubella country profile – Austria (2019)
- Measles and rubella country profile – Azerbaijan (2018)
- Measles and rubella country profile – Azerbaijan (2019)
- Measles and rubella country profile – Belarus (2018)
- Measles and rubella country profile – Belarus (2019)
- Measles and rubella country profile – Belgium (2018)
- Measles and rubella country profile – Belgium (2019)
- Measles and rubella country profile – Bosnia and Herzegovina (2018)
- Measles and rubella country profile – Bosnia and Herzegovina (2019)
- Measles and rubella country profile – Bulgaria (2018)
- Measles and rubella country profile – Bulgaria (2019)
- Measles and rubella country profile – Croatia (2018)
- Measles and rubella country profile – Croatia (2019)
- Measles and rubella country profile – Cyprus (2018)
- Measles and rubella country profile – Cyprus (2019)
- Measles and rubella country profile – Czech Republic (2018)
- Measles and rubella country profile – Czechia (2019)
- Measles and rubella country profile – Denmark (2018)
- Measles and rubella country profile – Denmark (2019)
- Measles and rubella country profile – Estonia (2018)
- Measles and rubella country profile – Estonia (2019)
- Measles and rubella country profile – Finland (2018)
- Measles and rubella country profile – Finland (2019)
- Measles and rubella country profile – France (2018)
- Measles and rubella country profile – France (2019)
- Measles and rubella country profile – Georgia (2018)
- Measles and rubella country profile – Georgia (2019)
- Measles and rubella country profile – Germany (2018)
- Measles and rubella country profile – Germany (2019)
- Measles and rubella country profile – Greece (2018)
- Measles and rubella country profile – Greece (2019)
- Measles and rubella country profile – Hungary (2018)
- Measles and rubella country profile – Hungary (2019)
- Measles and rubella country profile – Iceland (2018)
- Measles and rubella country profile – Iceland (2019)
- Measles and rubella country profile – Ireland (2018)
- Measles and rubella country profile – Ireland (2019)
- Measles and rubella country profile – Israel (2018)
- Measles and rubella country profile – Israel (2019)
- Measles and rubella country profile – Italy (2018)
- Measles and rubella country profile – Italy (2019)
- Measles and rubella country profile – Kazakhstan (2018)
- Measles and rubella country profile – Kazakhstan (2019)
- Measles and rubella country profile – Kyrgyzstan (2018)
- Measles and rubella country profile – Kyrgyzstan (2019)
- Measles and rubella country profile – Latvia (2018)
- Measles and rubella country profile – Latvia (2019)
- Measles and rubella country profile – Lithuania (2018)
- Measles and rubella country profile – Lithuania (2019)
- Measles and rubella country profile – Luxembourg (2018)
- Measles and rubella country profile – Luxembourg (2019)
- Measles and rubella country profile – Malta (2018)
- Measles and rubella country profile – Malta (2019)
- Measles and rubella country profile – Monaco (2019)
- Measles and rubella country profile – Montenegro (2018)
- Measles and rubella country profile – Montenegro (2019)
- Measles and rubella country profile – Netherlands (2018)
- Measles and rubella country profile – Netherlands (2019)
- Measles and rubella country profile – North Macedonia (2019)
- Measles and rubella country profile – Norway (2018)
- Measles and rubella country profile – Norway (2019)
- Measles and rubella country profile – Poland (2018)
- Measles and rubella country profile – Poland (2019)
- Measles and rubella country profile – Portugal (2018)
- Measles and rubella country profile – Portugal (2019)
- Measles and rubella country profile – Republic of Moldova (2018)
- Measles and rubella country profile – Republic of Moldova (2019)
- Measles and rubella country profile – Romania (2018)
- Measles and rubella country profile – Romania (2019)
- Measles and rubella country profile – Russian Federation (2018)
- Measles and rubella country profile – Russian Federation (2019)
- Measles and rubella country profile – San Marino (2019)
- Measles and rubella country profile – Serbia (2018)
- Measles and rubella country profile – Serbia (2019)
- Measles and rubella country profile – Slovakia (2018)
- Measles and rubella country profile – Slovakia (2019)
- Measles and rubella country profile – Slovenia (2018)
- Measles and rubella country profile – Slovenia (2019)
- Measles and rubella country profile – Spain (2018)
- Measles and rubella country profile – Spain (2019)
- Measles and rubella country profile – Sweden (2018)
- Measles and rubella country profile – Sweden (2019)
- Measles and rubella country profile – Switzerland (2018)
- Measles and rubella country profile – Switzerland (2019)
- Measles and rubella country profile – Tajikistan (2018)
- Measles and rubella country profile – Tajikistan (2019)
- Measles and rubella country profile – The former Yugoslav Republic of Macedonia (2018)
- Measles and rubella country profile – Turkey (2018)
- Measles and rubella country profile – Turkey (2019)
- Measles and rubella country profile – Turkmenistan (2018)
- Measles and rubella country profile – Turkmenistan (2019)
- Measles and rubella country profile – Ukraine (2018)
- Measles and rubella country profile – Ukraine (2019)
- Measles and rubella country profile – United Kingdom of Great Britain and Northern Ireland (2018)
- Measles and rubella country profile – United Kingdom of Great Britain and Northern Ireland (2019)
- Measles and rubella country profile – Uzbekistan (2018)
- Measles and rubella country profile – Uzbekistan (2019)
- Measles and rubella elimination 2015. Package for accelerated action: 2013-2015
- Measles and rubella elimination country profile - Albania (2020)
- Measles and rubella elimination country profile - Andorra (2020)
- Measles and rubella elimination country profile - Armenia (2020)
- Measles and rubella elimination country profile - Austria (2020)
- Measles and rubella elimination country profile - Azerbaijan (2020)
- Measles and rubella elimination country profile - Belarus (2020)
- Measles and rubella elimination country profile - Belgium (2020)
- Measles and rubella elimination country profile - Bosnia and Herzegovina (2020)
- Measles and rubella elimination country profile - Bulgaria (2020)
- Measles and rubella elimination country profile - Croatia (2020)
- Measles and rubella elimination country profile - Cyprus (2020)
- Measles and rubella elimination country profile - Czech Republic (2020)
- Measles and rubella elimination country profile - Estonia (2020)
- Measles and rubella elimination country profile - Finland (2020)
- Measles and rubella elimination country profile - France (2020)
- Measles and rubella elimination country profile - Georgia (2020)
- Measles and rubella elimination country profile - Germany (2020)
- Measles and rubella elimination country profile - Greece (2020)
- Measles and rubella elimination country profile - Hungary (2020)
- Measles and rubella elimination country profile - Iceland (2020)
- Measles and rubella elimination country profile - Ireland (2020)
- Measles and rubella elimination country profile - Israel (2020)
- Measles and rubella elimination country profile - Italy (2020)
- Measles and rubella elimination country profile - Kazakhstan (2020)
- Measles and rubella elimination country profile - Kyrgyzstan (2020)
- Measles and rubella elimination country profile - Latvia (2020)
- Measles and rubella elimination country profile - Lithuania (2020)
- Measles and rubella elimination country profile - Luxembourg (2020)
- Measles and rubella elimination country profile - Malta (2020)
- Measles and rubella elimination country profile - Monaco (2020)
- Measles and rubella elimination country profile - Montenegro (2020)
- Measles and rubella elimination country profile - Netherlands (2020)
- Measles and rubella elimination country profile - North Macedonia (2020)
- Measles and rubella elimination country profile - Norway (2020)
- Measles and rubella elimination country profile - Poland (2020)
- Measles and rubella elimination country profile - Portugal (2020)
- Measles and rubella elimination country profile - Republic of Moldova (2020)
- Measles and rubella elimination country profile - Romania (2020)
- Measles and rubella elimination country profile - Russian Federation (2020)
- Measles and rubella elimination country profile - San Marino (2020)
- Measles and rubella elimination country profile - Serbia (2020)
- Measles and rubella elimination country profile - Slovakia (2020)
- Measles and rubella elimination country profile - Slovenia (2020)
- Measles and rubella elimination country profile - Spain (2020)
- Measles and rubella elimination country profile - Sweden (2020)
- Measles and rubella elimination country profile - Switzerland (2020)
- Measles and rubella elimination country profile - Tajikistan (2020)
- Measles and rubella elimination country profile - Turkey (2020)
- Measles and rubella elimination country profile - Turkmenistan (2020)
- Measles and rubella elimination country profile - Ukraine (2020)
- Measles and rubella elimination country profile - United Kingdom (2020)
- Measles and rubella elimination country profile - Uzbekistan (2020)
- Measles Cases 1999-2011
- Meeting of Immunization Programme Managers in the WHO European Region (2014)
- Meeting of Regional and Global Specialized Polio Reference Laboratories of the WHO European Polio Laboratory Network
- Meeting of the European Regional Polio Laboratory Network (2017)
- Meeting of the Global Polio Laboratory Network (GPLN) in the WHO European Region
- Meeting of the Polio Laboratory Network of the WHO European Region (laboratories of the Russian Federation and newly independent states) (2016)
- Meetings of the measles/rubella laboratory network in the WHO European Region (2020)
- Messages: Why we need to invest in immunization
- Methods for assessing influenza vaccination coverage in target groups (2016)
- Myths and facts about immunization (2017)
- Ninth Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- Ongoing communication to build trust
- Operational considerations for influenza surveillance in the WHO European Region during COVID-19: interim guidance (2020) (produced by WHO/Europe)
- Operational guidance: acceptance and uptake of COVID-19 vaccines, January 2021 (produced by WHO/Europe)
- Operational guidance: COVID-19 immunization service delivery modalities, May 2021
- Operational guidance: COVID-19 vaccination data and information management, including monitoring of vaccine effectiveness, January 2021 (produced by WHO/Europe)
- Operational guidance: evidence-based decision-making process for developing national COVID-19 vaccination strategies, January 2021 (produced by WHO/Europe)
- Operational guidance: Health workforce and security, May 2021
- Operational guidance: legal and regulatory framework facilitating vaccine deployment, January 2021 (produced by WHO/Europe)
- Operational guidance: management structure, advocacy and resources for COVID-19 vaccine deployment and vaccination, January 2021 (produced by WHO/Europe)
- Pneumococcal vaccines: WHO position paper on their use in community outbreak settings – Utilisation des vaccins antipneumococciques dans le cadre de flambées épidémiques communautaires: note de synthèse de l’OMS (2021)
- Polio Outbreak Simulation Exercise (POSE) II
- Polio Outbreak Simulation Exercise IV report (2015)
- Polio Outbreak Simulation Exercise: How to test national preparedness plans using the POSE model (2015)
- Preparing for the introduction of HPV vaccine in the WHO European Region
- Preparing messages for decision-makers
- Prevention or treatment? How much health would a million dollars buy?
- Questions and answers about HPV. Facts about the virus and the vaccine (2017)
- Questions and answers about HPV. Information for health professionals (2017)
- Questions and answers about human papillomavirus (HPV)(2020)
- Recommendations on influenza vaccination during the 2019–2020 winter season (2019)
- Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season (2017)
- Regional Meeting of National Immunization Programme Managers
- Report of the 26th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication
- Responding to concerns about vaccination
- Responding to myths about immunization
- Review of evidence on equitable delivery, access and utilization of immunization services for migrants and refugees in the WHO European Region (A) (2017)
- Review of vaccine price data: submitted by WHO European Region Member States through the WHO/UNICEF Joint Reporting Form for 2013 (2015)
- Risk scales - fear the disease, not the vaccine
- Risk scales: benefits of vaccines far outweigh the risks (2017)
- Second European Immunization Week meeting
- Second meeting of the European Regional Verification Commission for measles and rubella elimination
- Setting the immunization agenda through advocacy and communication
- Setting the media agenda
- Seventh Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- Situation report #3, December 2019
- Sixth Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE)
- Societal benefits of immunization (2017)
- Strategic considerations in preparing for deployment of COVID-19 vaccine and vaccination in the WHO European Region, 9 October 2020 (produced by WHO/Europe)
- Strategic Response Plan for the measles emergency in the WHO European Region (September 2019–December 2020)
- Surveillance guidelines for measles, rubella and congenital rubella syndrome in the WHO European Region, update December 2012
- Tailoring Immunization Programmes (TIP): Outputs of pilot implementation in Bulgaria (2014)
- Tailoring immunization programmes for seasonal influenza (TIP FLU) - A guide for increasing pregnant women’s uptake of seasonal influenza vaccination (2017)
- Tailoring immunization programmes for seasonal influenza (TIP FLU). Understanding health care workers’ uptake of seasonal influenza vaccination in Montenegro: a case study for policy-makers and programme managers
- Talking with Parents about Vaccines for Children
- Talking with patients and parents about HPV vaccination for girls: Information for health care professionals
- TIP evaluation report (2017)
- TIP guide infographic
- TIP Tailoring Immunization Programmes (2019)
- Training manual: Vaccine safety and false contraindications to vaccination (2017)
- Vaccination and trust (2017)
- Vaccine safety events: managing the communications response
- Vaccine safety messages
- Vaccine safety messages (frequency of AEFIs) (2017)
- Vaccine-preventable diseases: Signs, symptoms & complications
- Verification of measles and rubella elimination in the WHO European Region. Report on a series of intercountry meetings. October 2012 – February 2013
- WHO EpiBrief 2/2013
- WHO EpiBrief No. 1/2014
- WHO EpiBrief, No. 1/2018
- WHO EpiBrief, No. 1/2019
- WHO EpiBrief, No. 1/2020
- WHO EpiBrief, No. 1/2021
- WHO EpiBrief, No. 2/2018
- WHO EpiBrief, No. 2/2019
- WHO EpiBrief, No. 2/2020
- WHO EpiData, April 2013–March 2014
- WHO EpiData, April 2017 - March 2018
- WHO EpiData, August 2016-July 2017
- WHO EpiData, December 2012–November 2013
- WHO Epidata, December 2017 - November 2018
- WHO EpiData, February 2016–January 2017
- WHO EpiData, February 2017 - January 2018
- WHO EpiData, January - December 2017
- WHO EpiData, January 2013–December 2013
- WHO EpiData, January–December 2016
- WHO EpiData, July 2013–June 2014
- WHO EpiData, June 2017 - May 2018
- WHO EpiData, March 2017 - February 2018
- WHO EpiData, May 2013–April 2014
- WHO EpiData, May 2017 - April 2018
- WHO EpiData, No. 1/2019, January 2018 - December 2018
- WHO EpiData, No. 10/2019, October 2018—September 2019
- WHO EpiData, No. 11/2019, November 2018—October 2019
- WHO EpiData, No. 12/2019, December 2018—November 2019
- WHO EpiData, No. 2/2019, February 2018 - January 2019
- WHO EpiData, No. 3/2019, March 2018—February 2019
- WHO EpiData, No. 4/2019, April 2018—March 2019
- WHO EpiData, No. 5/2019, May 2018—April 2019
- WHO EpiData, No. 6/2019, June 2018—May 2019
- WHO EpiData, No. 7/2019, July 2018—June 2019
- WHO EpiData, No. 8/2019, August 2018—July 2019
- WHO EpiData, No. 9/2019, September 2018—August 2019
- WHO EpiData, November 2012–October 2013
- WHO EpiData, November 2013–October 2014
- WHO EpiData, November 2016-October 2017
- WHO Epidata, November 2017 - October 2018
- WHO EpiData, October 2012–September 2013
- WHO EpiData, October 2015–September 2016
- WHO Epidata, October 2017 - September 2018
- WHO Epidata, September 2017 - August 2018
- WHO Epidemiological Brief 9: polio outbreak in the European Region and country responses
- WHO European Regional measles/rubella LabNet meeting for western and central European countries, Turkey and Georgia (2016)
- WHO meeting on strengthening measles and rubella laboratory network in the Russian Federation and newly independent states
- WHO meeting on strengthening the Measles and Rubella Lab Network in the Russian Federation and newly independent states
- WHO meeting on strengthening the measles and rubella laboratory network in the Russian Federation and newly independent states
- WHO regional meeting on new vaccines introduction experience and issues
- WHO Regional Office for Europe recommendations on influenza vaccination during the 2017/2018 winter season (September 2017)
- WHO Regional Office for Europe recommendations on influenza vaccination for the 2020/2021 season during the ongoing COVID-19 pandemic (2020)
- Why is EIW important?
- Workbook – Advocacy for sustainable funding of immunization programmes
- Workshop on laboratory diagnosis of diphtheria. Report (2018)
- Workshop on prevention and treatment of childhood pneumonia and diarrhoea (2014)
